Common Reviewer Comments in Global Stability Assessments
Stability data plays a pivotal role in global regulatory submissions, yet it’s also one of the most frequently scrutinized areas. Whether submitting to the USFDA, EMA, WHO, or regional authorities like CDSCO and ANVISA, pharma companies often receive a wave of comments specific to stability protocols, data presentation, and justification strategies. In this listicle, we’ll…
Read More “Common Reviewer Comments in Global Stability Assessments” »